Early Stage Alzheimer’s Treatment
FDA grants standard approval of Alzheimer’s drug, marking a new milestone for the disease that impacts millions of Americans. Trial data showed that the treatment slows the progression by 27% for patients in the earliest stages of Alzheimer’s. The U.S. Food and Drug Administration on Thursday granted traditional approval to the Alzheimer’s drug lecanemab, known by the
Early Stage Alzheimer’s Treatment Read More »





